Epidemiology of COPD Prof. David M. Mannino, M.D.

Size: px
Start display at page:

Download "Epidemiology of COPD Prof. David M. Mannino, M.D."

Transcription

1 Epidemiology of COPD David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health College of Public Health University of Kentucky 1 Outline Definitions Severity Progression Prevalence Hospitalizations Mortality 2 COPD definition GOLD 2010 Characterized by chronic airflow limitation and a range of pathologic changes in the lung, significant extrapulmonary effects, and important comorbidities Features may include: Chronic bronchitis (cough and sputum production) Emphysema (destruction of gas exchanging surfaces of the lung) 3 The screen versions of these slides have full details of copyright and acknowledgements 1

2 COPD definition Chronic Bronchitis Emphysema Irreversible Airflow Obstruction 4 AJRCCM 1995 ; 152: S Asthma Reversible Airflow Obstruction Lung function categories FEV 1 % predicted Gold 1 Gold 2 Gold 3 Gold 0 (if symptoms) or normal Restricted 20 0 Gold 4 FEV 1 /FVC < 70% FEV 1 /FVC => 70% 5 GOLD Guidelines 2010, Mannino et al., Resp Med, 2006 FEV 1 /FVC (%) 74 Potentially underdiagnosed Lower limit of normal Potentially overdiagnosed Age ( Years ) 6 Mannino et al., Thorax 2007; 62: The screen versions of these slides have full details of copyright and acknowledgements 2

3 Lung function in 1000 COPD patients 14% 30% 7 Kohler, D. et al., Thorax 2003; 58: 825 COPD severity - U.S Current Smokers Former Smokers Never Smokers 8 GOLD 3 GOLD 2 GOLD 1 Mannino DM, Watt G, Hole D, et al., Eur Respir J. 2006; 27: COPD severity - England 9 Thorax 2006; 61: The screen versions of these slides have full details of copyright and acknowledgements 3

4 COPD severity - BOLD 10 Lancet 2007; 370: COPD progression 11 Fletcher et al., The Natural History of Chronic Bronchitis and Emphysema, 1976 COPD progression (2) Age Death FEV 1 (%) relative to age 25 Symptoms Disability Susceptible Smokers Not Susceptible Stopped smoking at 45 (mild COPD) Stopped smoking at 65 (severe COPD) Age (years) 12 Adapted from Fletcher CM, Peto R. Br Med J. 1977; 1: 1645 The screen versions of these slides have full details of copyright and acknowledgements 4

5 Natural history of chronic airflow obstruction 13 Med Clinics North America 1981; 65: FEV 1 decline from pivotal studies FEV 1 (% of age-predicted) Fletcher Peto: Smokers (modified) LHS: Usual care LHS: Smoking intervention UPLIFT: Tiotropium TORCH: SFC LHS UPLIFT TORCH Data from Fletcher C. Br Med J. 1977; 1 : ; Anthonisen NR et al., JAMA 1994; 272: ; Celli BR et al., AJRCCM 2008; 178: Disease progression by COPD severity FEV 1 (% of age-adjusted reference value) GOLD II GOLD III GOLD IV 15 Age (years) Adapted from Decramer M., Cooper CB., Thorax 2010; 65: The screen versions of these slides have full details of copyright and acknowledgements 5

6 What is progression of COPD? Health Incident Disease 16 0 At Risk Restriction I Mild Pneumonol. Alergol. Pol.2011; 79 (2): II Moderate III Severe Progressive Disease Prevalent Disease Death IV Very Severe??? Diagnosed lung disease and lung function impairment in the U.S. adult population Asthma 5.5% Chronic bronchitis 3.2% Emphysema 1.5% Airflow obstruction int. 1.6% Airflow obstruction ext. 3.1% NHANES III NHANES III Current Diseases as a Proportional Venn Diagram Soriano et al., Chest2003; 124: Outline Definitions Severity Progression Prevalence Hospitalizations Mortality 18 The screen versions of these slides have full details of copyright and acknowledgements 6

7 Prevalence of COPD Prevalence per Midpoint of age-range population studied 19 Halbert et al., Chest2003; 123: Opinion Diagnosis Symptoms Spirometry Prevalence of COPD 2006 update GOLD 2 + GOLD 1 + ERS (LLN) ATS (ratio 75%) Other Overall Halbert et al., ERJ 2006; 28: Prevalence of COPD 2006 update (2) Africa Americas E. Mediterranean Europe SE Asia W. Pacific???? Halbert et al., ERJ 2006; 28: The screen versions of these slides have full details of copyright and acknowledgements 7

8 22 BOLD sites 23 Prevalence of GOLD 2 COPD 25 Prevalence per Men Women South Africa Phillipines Turkey Poland USA Mannino and Buist, Lancet2007 Norway Austria Uraguay China Canada Australia Germany Iceland Venezuela Chile Brazil Mexico The screen versions of these slides have full details of copyright and acknowledgements 8

9 COPD prevalence, by sex, in U.S., (GOLD 2 or higher) Millions of adults aged 25 and older Mannino DM, et al., MMWR 2002; 51(SS-6): 1 20 Men - GOLD 2 Women - GOLD 2 Decreasing prevalence in Spain? 26 Eur Respir J. 2010; 36: No increase in Finland 27 Eur Respir J. 2010; 36: The screen versions of these slides have full details of copyright and acknowledgements 9

10 Risk of COPD among smokers 28 Buist et al., Lancet 2007 Risk of COPD by age (10 year increase) 29 Buist et al., Lancet Risk factors of GOLD 2 COPD in never smoking men Age Comorbid Disease BMI Lamprecht et al., Chest2011 The screen versions of these slides have full details of copyright and acknowledgements 10

11 100 Risk factors of GOLD 2 COPD in never smoking women Age Comorbid Disease BMI Lamprecht et al., Chest2011 Biomass fuel and COPD in China 32 Liu et al., Thorax 2007; 62: Early life exposures For stage 2 or higher COPD 33 Svanes et al., Thorax 2010 The screen versions of these slides have full details of copyright and acknowledgements 11

12 Early life exposures (2) For stage 2 or higher COPD 34 Svanes et al., Thorax 2010 Outline Definitions Severity Progression Prevalence Hospitalizations Mortality 35 A paradigm of exacerbations Death Hospitalizations Exacerbations Symptoms Population at risk 36 Johnston et al., Epidemiology of COPD Exacerbations in Exacerbations of COPD, Informa 2008 The screen versions of these slides have full details of copyright and acknowledgements 12

13 COPD Asthma At risk Symptoms Exacerbations Hospitalizations Death 37 Johnston et al., Epidemiology of COPD Exacerbations in Exacerbations of COPD, Informa COPD exacerbation rate Mean rates per person per year Studies ordered chronologically Johnston et al., Epidemiology of COPD Exacerbations in Exacerbations of COPD, Informa 2008 COPD hospitalization rate 3 Hospitalizations per person per year Population-based Hospital based 39 Johnston et al., Epidemiology of COPD Exacerbations in Exacerbations of COPD, Informa 2008 The screen versions of these slides have full details of copyright and acknowledgements 13

14 End-of-Life disease C Each event in a COPD patient has the potential to be lethal 40 Lorenz et al., Ann Intern Med : COPD hospitalizations U.S. ( ) 41 Mannino DM, et al., MMWR 2002; 51 (SS-6): 1 20 COPD hospitalizations U.S. ( ) 42 Brown DW, et al., JCOPD 2010 The screen versions of these slides have full details of copyright and acknowledgements 14

15 Long-term follow-up of U.S. cohorts Garcia-Aymerich et al., Thorax 2011 Time to COPD hospitalization Analysis time gold = normal gold = restrictive gold = gold 0 gold = gold 1 gold = gold 2 gold = gold 3/4 Risk of death following COPD hospitalization Hazard ratio (95% CI) Long-term follow-up of U.S. cohorts Time to death following a COPD hospitalization 45 Garcia-Aymerich et al., Thorax 2011 The screen versions of these slides have full details of copyright and acknowledgements 15

16 Risk of hospitalization 100 With 3 comorbid diseases With 2 comorbid diseases With 1 comorbid disease With no comorbid disease 10 1 GOLD 3/4 GOLD 2 GOLD 1 Restricted GOLD 0 Normal 46 Models adjusted for age, sex, race, smoking status, education level, and body mass index Mannino et al., ERJ 2008 Outline Definitions Severity Progression Prevalence Hospitalizations Mortality 47 End-of-Life disease C Each event in a COPD patient has the potential to be lethal Lorenz et al., Ann Intern Med 2008: 148: The screen versions of these slides have full details of copyright and acknowledgements 16

17 Survival by lung function impairment Normal GOLD 1 GOLD 0 Restricted GOLD 2 GOLD 3 or 4 49 Mannino et al., Resp Med 2006 What do COPD patients die from? (rate per 1,000 person-years) Normal Restricted GOLD 0 GOLD 1 GOLD 2 GOLD 3/ COPD ASCVD Lung cancer Other Mannino et al., Resp Med, Jan 2006 COPD consequences and comorbidities 51 COPD 2008; 5: The screen versions of these slides have full details of copyright and acknowledgements 17

18 Risk of death within 5 years from baseline 100 With 3 Comorbid Diseases With 2 Comorbid Diseases With 1 Comorbid Disease With No Comorbid Disease 10 1 GOLD 3/4 GOLD 2 GOLD 1 Restricted GOLD 0 Normal 52 Models adjusted for age, sex, race, smoking status, education level, and body mass index Mannino et al., ERJ 2008 Mortality following exacerbation 53 Roede et al., Thorax 2008 COPD deaths by sex, race; U.S., Mannino DM, et al., MMWR 2002; 51(SS-6): 1 20 The screen versions of these slides have full details of copyright and acknowledgements 18

19 COPD deaths by region; U.S., Southern All except California California NJ, NY 55 Polednak, AP, JCOPD 2010 Spain improving survival after COPD hospitalization 56 Thorax 2010; 65: Improving COPD mortality in U.S. 57 Chest2011 (In press) The screen versions of these slides have full details of copyright and acknowledgements 19

20 Conclusions The epidemiology of COPD continues to evolve Prevalence is related to different factors in different parts of the world, although tobacco smoke remains the most important exposure COPD hospitalizations are important and costly They may be decreasing 58 Conclusions (2) COPD is a leading cause of mortality Risk of death may be decreasing in the US and other countries 59 Chronic obstructive pulmonary disease COPD is a PREVENTABLE and TREATABLE disease 60 ATS/ERS Guidelines for the Treatment of COPD, 2004 The screen versions of these slides have full details of copyright and acknowledgements 20

21 61 The screen versions of these slides have full details of copyright and acknowledgements 21

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum

COPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum COPD in Korea Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum Mortality Rate 1970-2002, USA JAMA,2005 Global Burden of Disease: COPD WHO & World

More information

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines

More information

American Thoracic Society (ATS) Perspective

American Thoracic Society (ATS) Perspective National Surveillance System for Chronic Lung Disease (CLD): American Thoracic Society (ATS) Perspective Gerard J. Criner, M.D. Chronic Obstructive Pulmonary Disease (COPD) l Definition: Group of chronic

More information

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST

More information

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST

More information

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease

More information

COPD: Current Medical Therapy

COPD: Current Medical Therapy COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for

More information

Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with

Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK Affiliated with COPD and Comorbidities Norbert Berend Professor Emeritus University of Sydney Head, Respiratory Research The George Institute

More information

Silica dust and COPD, is there an association?

Silica dust and COPD, is there an association? Silica dust and COPD, is there an association? K. Ulm Institute for Medical Statistics and Epidemiology University of Technology, Munich Germany 1 Outline: - what is COPD? - some fact about COPD - what

More information

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #51 (NQF 0091): Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center

COPD UPDATE ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center COPD UPDATE 2012 ıdr Shitrit David ıhead of the Pulmonary Department ımeir Medical Center Definition of COPD COPD is a preventable and treatable disease with some significant extra pulmonary effects that

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

UNDERSTANDING COPD MEDIA BACKGROUNDER

UNDERSTANDING COPD MEDIA BACKGROUNDER UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the

More information

Chronic obstructive pulmonary disease (COPD) is a major case of chronic morbidity

Chronic obstructive pulmonary disease (COPD) is a major case of chronic morbidity 26 Journal of the association of physicians of india march 2014 VOL. 62 Original Article Early Detection of Chronic Obstructive Pulmonary Disease in Asymptomatic Smokers using Spirometry MS Barthwal *,

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

C hronic obstructive pulmonary disease (COPD) is one of

C hronic obstructive pulmonary disease (COPD) is one of 935 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Developing COPD: a 25 year follow up study of the general population A Løkke, P Lange, H Scharling, P Fabricius, J Vestbo... See end of article for authors affiliations...

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and

More information

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,

More information

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.

More information

COPD and environmental risk factors other than smoking. 14. Summary

COPD and environmental risk factors other than smoking. 14. Summary COPD and environmental risk factors other than smoking 14. Summary Author : P N Lee Date : 7 th March 2008 1. Objectives and general approach The objective was to obtain a good insight from the available

More information

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

Aboriginal lung health and lung function. Graham Hall Telethon Kids Institute and Curtin University

Aboriginal lung health and lung function. Graham Hall Telethon Kids Institute and Curtin University Aboriginal lung health and lung function Graham Hall Telethon Kids Institute and Curtin University Why Lung function? Lung function underpins clinical respiratory medicine, vital to: diagnosis of lung

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Online Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey

Online Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang

More information

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013

COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory

More information

Disease progression in COPD:

Disease progression in COPD: Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

Around-COPD Verona (Italy), January Highlights

Around-COPD Verona (Italy), January Highlights Introduction Around-COPD Verona (Italy), January 18 2017 Highlights Prof. Dal Negro chairman of the symposium, opened the congress by highlighting the burden of COPD as a chronic invalidating disease affecting

More information

E. Prescott + **, P. Lange* +, J. Vestbo**

E. Prescott + **, P. Lange* +, J. Vestbo** Eur Respir J, 1995, 8, 1333 1338 DOI: 10.1183/09031936.95.08081333 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Chronic mucus hypersecretion

More information

Cigarette Smoking and Lung Obstruction Among Adults Aged 40 79: United States,

Cigarette Smoking and Lung Obstruction Among Adults Aged 40 79: United States, NCHS Data Brief No. 8 January 25 Cigarette Smoking and Lung Obstruction Among Adults Aged 4 79: United States, 27 22 Ryne Paulose-Ram, Ph.D., M.A.; Timothy Tilert, B.S.; Charles F. Dillon, M.D., Ph.D.;

More information

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation : The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease

More information

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former

More information

Potential risks of ICS use

Potential risks of ICS use Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk

More information

Chronic Obstructive Pulmonary Disease Surveillance --- United States,

Chronic Obstructive Pulmonary Disease Surveillance --- United States, University of Kentucky From the SelectedWorks of David M. Mannino October, 2002 Chronic Obstructive Pulmonary Disease Surveillance --- United States, 1971--2000 David M. Mannino David M. Homa Lara J. Akinbami

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

T he recent international guidelines from the Global

T he recent international guidelines from the Global 842 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study A Johannessen, E R Omenaas, P

More information

Evidence for early Pulmonary Rehabilitation following hospitalisation for exacerbation of COPD

Evidence for early Pulmonary Rehabilitation following hospitalisation for exacerbation of COPD Centre for Inflammation Research Evidence for early Pulmonary Rehabilitation following hospitalisation for exacerbation of COPD Pulmonary Rehabilitation Clinicians Day Roberto A. Rabinovich ELEGI/Colt

More information

COPD: Genomic Biomarker Status and Challenge Scoring

COPD: Genomic Biomarker Status and Challenge Scoring COPD: Genomic Biomarker Status and Challenge Scoring Julia Hoeng, PMI R&D Raquel Norel, IBM Research 3 rd October 2012 COPD: Genomic Biomarker Status Julia Hoeng, Ph.D. Philip Morris International, Research

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

Available online at Scholars Research Library

Available online at   Scholars Research Library Available online at www.scholarsresearchlibrary.com Annals of Biological Research, 2010, 1 (4) : 248-253 (http://scholarsresearchlibrary.com/archive.html) ISSN 0976-1233 CODEN (USA): ABRNBW A study on

More information

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado

More information

Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli

Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre Overlap asma BPCO. Dr. Marco Contoli Asma, BPCO ed Esercizio Fisico Ferrara, 6 e 7 Novembre 2015 Overlap asma BPCO Dr. Marco Contoli Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara (Sept.

More information

Pathophysiology of COPD 건국대학교의학전문대학원

Pathophysiology of COPD 건국대학교의학전문대학원 Pathophysiology of COPD 건국대학교의학전문대학원 내과학교실 유광하 Rate per 100 0,000 population 550 500 450 400 350 300 250 200 150 100 50 0 Heart disease Cancer Stroke 1970 1974 1978 1982 1986 1990 1994 1998 2002 Year of

More information

Curriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital

Curriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI

More information

Shaping a Dynamic Future in Respiratory Practice. #DFResp

Shaping a Dynamic Future in Respiratory Practice. #DFResp Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE Chronic Obstructive Pulmonary Disease (COPD) is a slowly progressive disease of the airways that is characterized by a gradual loss of lung function. In the U.S.,

More information

General Meeting of the Global Alliance against Chronic Respiratory Diseases (GARD) and GARD Launch

General Meeting of the Global Alliance against Chronic Respiratory Diseases (GARD) and GARD Launch General Meeting of the Global Alliance against Chronic Respiratory Diseases (GARD) and GARD Launch 28-29 March 2006 Beijing, People s Republic of China Wednesday, 29 March 2006 Session 2: Working Groups.

More information

Addressing Undertreatment

Addressing Undertreatment Objectives TOWARD BETTER COPD OUTCOMES The Critical Role of Primary Care for Early Diagnosis and Guideline-directed Management Keith Robinson, MD, MS, FCCP Pulmonary Physicians of South Florida, LLC Fusion

More information

Research Article Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD

Research Article Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD Pulmonary Medicine Volume 2011, Article ID 780215, 6 pages doi:10.1155/2011/780215 Research Article Subjects with Discordant Airways Obstruction: Lost between Spirometric Definitions of COPD Bernd Lamprecht,

More information

COPO Prevalence in Southeastem Kentucky* The Burden of Lung Disease Study

COPO Prevalence in Southeastem Kentucky* The Burden of Lung Disease Study Original Research COPD COPO Prevalence in Southeastem Kentucky* The Burden of Lung Disease Study Jennifer N. Methvin, MPH; David M. Mannino, MD, FCCP; and Baretta R. Casey, MD Background: The Burden ofobstructive

More information

Productivity losses in chronic obstructive pulmonary disease a population-based survey.

Productivity losses in chronic obstructive pulmonary disease a population-based survey. Online supplement to Productivity losses in chronic obstructive pulmonary disease a population-based survey. Running head: Productivity losses in COPD. Authors: Marta Erdal, Department of Thoracic Medicine,

More information

Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health

Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) November 29, 2017 Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management Priority Health Top 5 Causes of Death

More information

Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe

More information

Asthma COPD Overlap (ACO)

Asthma COPD Overlap (ACO) Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma

More information

The effects of secondhand smoke on chronic obstructive pulmonary disease in nonsmoking Korean adults

The effects of secondhand smoke on chronic obstructive pulmonary disease in nonsmoking Korean adults ORIGINAL ARTICLE Korean J Intern Med 2014;29:613-619 The effects of secondhand smoke on chronic obstructive pulmonary disease in nonsmoking Korean adults Woong Jun Kim 1, June Seok Song 2, Dong Won Park

More information

TLALELETSO. Chronic Lung Disease

TLALELETSO. Chronic Lung Disease dates for your practice June, 2013. Vol 2, Issue 18 TLALELETSO Chronic Lung Disease This issue is focused on chronic lung disease. We discuss diagnosis, management and prevention, focusing on the importance

More information

How To Assess Severity and Prognosis

How To Assess Severity and Prognosis How To Assess Severity and Prognosis Gregory Tino, M.D. Chief, Department of Medicine Penn Presbyterian Medical Center Associate Professor of Medicine Perelman School of Medicine at the University of Pennsylvania

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH

More information

COPD or not COPD, that is the question.

COPD or not COPD, that is the question. COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP

More information

Objectives. Advances in Managing COPD Patients

Objectives. Advances in Managing COPD Patients 4:45 5:30pm Advances in Managing Patients SPEAKER Nicola Hanania, MD, FCCP, FRCP, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Nicola Hanania, MD,

More information

Prevalence of Chronic Obstructive Lung Disease in Korea Using Data from the Fifth Korea National Health and Nutrition Examination Survey

Prevalence of Chronic Obstructive Lung Disease in Korea Using Data from the Fifth Korea National Health and Nutrition Examination Survey http://dx.doi.org/0.4082/kjfm.205.36.3.28 Korean J Fam Med 205;36:28-34 eissn: 2092-675 Original Article Prevalence of Chronic Obstructive Lung Disease in Korea Using Data from the Fifth Korea National

More information

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease

More information

Reduced lung function in midlife and cognitive impairment in the elderly

Reduced lung function in midlife and cognitive impairment in the elderly Page 1 of 5 Reduced lung function in midlife and cognitive impairment in the elderly Giuseppe Verlato, M.D. Ph.D Department of Diagnostics and Public Health University of Verona Verona, Italy Mario Olivieri,

More information

Prevalence of Chronic Obstructive Pulmonary Disease and Tobacco Use in Veterans at Boise Veterans Affairs Medical Center

Prevalence of Chronic Obstructive Pulmonary Disease and Tobacco Use in Veterans at Boise Veterans Affairs Medical Center Prevalence of Chronic Obstructive Pulmonary Disease and Tobacco Use in Veterans at Boise Veterans Affairs Medical Center William H Thompson MD and Sophie St-Hilaire DVM PhD BACKGROUND: Although its prevalence

More information

Risks for respiratory NCDs from exposure to HAP: an overview of the evidence. Dr Nigel Bruce, University of Liverpool, UK

Risks for respiratory NCDs from exposure to HAP: an overview of the evidence. Dr Nigel Bruce, University of Liverpool, UK Risks for respiratory NCDs from exposure to HAP: an overview of the evidence Dr Nigel Bruce, University of Liverpool, UK Overview Life course perspective useful Disease risks How may inter-relate over

More information

They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation

They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation They Can t Bury You while You re Still Moving: Update on Pulmonary Rehabilitation Richard ZuWallack, MD Associate Chief, Pulmonary and Critical Care St. Francis Hospital, Hartford, CT Professor of Medicine

More information

COPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012

COPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012 COPD Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012 Attitude It is a disease on which a good deal of wholly, unmerited

More information

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD

More information

COPD Prevalence in Salzburg, Austria* Results From the Burden of Obstructive Lung Disease (BOLD) Study

COPD Prevalence in Salzburg, Austria* Results From the Burden of Obstructive Lung Disease (BOLD) Study Original Research COPD COPD Prevalence in Salzburg, Austria* Results From the Burden of Obstructive Lung Disease (BOLD) Study Lea Schirnhofer, MD; Bernd Lamprecht, MD; William M. Vollmer, PhD; Michael

More information

The global burden of chronic respiratory diseases

The global burden of chronic respiratory diseases Key points Currently, the serious consequences of chronic diseases and their risk factors are not fully recognised by the international health community. In the period of 1990 2020, COPD deaths are expected

More information

COPD as a comorbidity of heart failure in elderly patients

COPD as a comorbidity of heart failure in elderly patients COPD as a comorbidity of heart failure in elderly patients Professor Mitja Lainscak, MD, PhD, FESC, FHFA Departments of Cardiology and Research&Education, General Hospital Celje Faculty of Medicine, University

More information

Respiratory diseases in Ostrołęka County

Respiratory diseases in Ostrołęka County Respiratory diseases in Ostrołęka County 4400 persons underwent examination 950 persons were given referrals to more detailed investigation 600 persons were examined so far The results of more detailed

More information

C hronic obstructive pulmonary disease (COPD) is an

C hronic obstructive pulmonary disease (COPD) is an 388 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study D M Mannino, A S Buist,

More information

Disclosures. Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease (COPD)

Disclosures. Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease May 14, 2016 Orlando, FL COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United States. Alarmingly, COPD recently became

More information

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index Chronic Respiratory Disease 2009; 6: 75 80 http://crd.sagepub.com ORIGINAL PAPER Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

More information

Exposure to Indoor Biomass Fuel Pollutants and Asthma Prevalence in Southeastern Kentucky: Results From the Burden of Lung Disease (BOLD) Study

Exposure to Indoor Biomass Fuel Pollutants and Asthma Prevalence in Southeastern Kentucky: Results From the Burden of Lung Disease (BOLD) Study University of Kentucky From the SelectedWorks of David M. Mannino September, 2010 Exposure to Indoor Biomass Fuel Pollutants and Asthma Prevalence in Southeastern Kentucky: Results From the Burden of Lung

More information

Karen Meyerson, MSN, APRN, NP C, AE C

Karen Meyerson, MSN, APRN, NP C, AE C Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) June 2015 Karen Meyerson, MSN, APRN, NP C, AE C Patient Education The goal of all patient education is to help patients take the actions

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They

More information

Key words: asthma; COPD; epidemiology; obstructive lung disease; Venn diagram

Key words: asthma; COPD; epidemiology; obstructive lung disease; Venn diagram The Proportional Venn Diagram of Obstructive Lung Disease* Two Approximations From the United States and the United Kingdom Joan B. Soriano, MD; Kourtney J. Davis, PhD; Bobbie Coleman, BSc; George Visick,

More information

Chronic Obstructive Pulmonary Disease Guidelines and updates

Chronic Obstructive Pulmonary Disease Guidelines and updates Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United

More information

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other

More information

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures

11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical

More information

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective

More information

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification

Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification ORIGINAL ARTICLE COPD Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification Paul W. Jones 1, Lukasz Adamek 2, Gilbert Nadeau 2 and Norbert Banik 3 Affiliations:

More information

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08 Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes

More information

What do pulmonary function tests tell you?

What do pulmonary function tests tell you? Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical

More information

Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study

Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study ORIGINAL ARTICLE COPD Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study Masaru Suzuki 1, Hironi Makita 1, Yoichi M. Ito 2, Katsura Nagai 1, Satoshi Konno 1 and Masaharu

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published

More information

Alpha1-register in Lithuania Brigita Sitkauskiene, MD, PhD

Alpha1-register in Lithuania Brigita Sitkauskiene, MD, PhD Alpha1-register in Lithuania Brigita Sitkauskiene, MD, PhD Assoc.Professor and Head Division for Clinical Immunology and Allergology Kaunas University of Medicine, Lithuania Malmö 2008 K A U N A S Kaunas

More information

COPD most commonly refers to chronic bronchitis, Mild and Moderate-to-Severe COPD in Nonsmokers* Distinct Demographic Profiles

COPD most commonly refers to chronic bronchitis, Mild and Moderate-to-Severe COPD in Nonsmokers* Distinct Demographic Profiles Mild and Moderate-to-Severe COPD in Nonsmokers* Distinct Demographic Profiles Carolyn E. Behrendt, PhD Study objective: To investigate the risk of COPD among nonsmokers. Design: Case-control study, logistic

More information